Patients and Methods Between October 1999 and October 2001, 416 eligible patients with prostate cancer were assigned to one of three treatment groups according to their risk factors 181 low risk patients were treated with 3DCRT alone, 75 intermediate risk patients were allocated to receive neoadjuvant AD NAD 4 6 months before and during 3DCRT; and 160 high risk patients received NAD and adjuvant AD AAD 2 years after 3DCRT <a href=https://cialis.mom>cialis 40 mg</a>
